0000899243-19-026599.txt : 20191104 0000899243-19-026599.hdr.sgml : 20191104 20191104175407 ACCESSION NUMBER: 0000899243-19-026599 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191104 FILED AS OF DATE: 20191104 DATE AS OF CHANGE: 20191104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ozawa Clare CENTRAL INDEX KEY: 0001746742 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 191190938 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER NAME: FORMER CONFORMED NAME: Clare Ozawa DATE OF NAME CHANGE: 20180716 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-04 0 0001720725 Oyster Point Pharma, Inc. OYST 0001746742 Ozawa Clare C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON NJ 08540 1 0 0 0 Common Stock, par value $0.001 per share 2019-11-04 4 C 0 1941500 A 1941500 I See footnotes Common Stock, par value $0.001 per share 2019-11-04 4 C 0 495388 A 2436888 I See footnotes Common Stock, par value $0.001 per share 2019-11-04 4 P 0 125000 16.00 A 2561888 I See footnotes Common Stock, par value $0.001 per share 2019-11-04 4 C 0 566158 A 566158 I See footnotes Common Stock, par value $0.001 per share 2019-11-04 4 P 0 437500 16.00 A 1003658 I See footnotes Series A Convertible Preferred Stock 2019-11-04 4 C 0 1941500 D Common Stock, par value $0.001 per share 1941500 0 I See footnotes Series B Convertible Preferred Stock 2019-11-04 4 C 0 495388 D Common Stock, par value $0.001 per share 495388 0 I See footnotes Series B Convertible Preferred Stock 2019-11-04 4 C 0 566158 D Common Stock, par value $0.001 per share 566158 0 I See footnotes These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. Shares held by Versant Vantage I, L.P. and may be deemed beneficially owned by the Reporting Person by reason of the Reporting Person being a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, L.P. Shares held by Versant Venture Capital VI, L.P. ("Versant VI") and may be deemed beneficially owned by the Reporting Person as of November 1, 2019 upon becoming a managing member of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P., the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. /s/Jeffrey Nau, Attorney-in-fact 2019-11-04